Sumitomo Pharma's DSP-3077 Receives FDA Orphan Drug Designation for RP Treatment Sumitomo Pharma America announces that DSP-3077 has received Orphan Drug designation from the FDA for treating retinitis pigmentosa, addressing urgent patient needs.

Sumitomo Pharma's DSP-3077 Receives FDA Orphan Drug Designation for RP Treatment #United_States #Marlborough #Sumitomo_Pharma #Orphan_Drug #DSP-3077

ReviR Therapeutics Marks Significant Clinical Milestone in Rare Disease Treatments and Expands Operations in China ReviR Therapeutics announces the first dosing in its Phase 1 study and gains CDE clearance for orphan drug indications in China, forging new paths for US expansion.

ReviR Therapeutics Marks Significant Clinical Milestone in Rare Disease Treatments and Expands Operations in China #United_States #San_Francisco #ReviR_Therapeutics #Orphan_Drug #RTX-117

SN BioScience's Innovative SNB-101 Receives FDA's Orphan Drug Designation for Gastric Cancer Treatment SN BioScience's SNB-101, a groundbreaking nanoparticle anticancer drug, has received Orphan Drug Designation from the FDA for gastric cancer, offering hope to patients.

SN BioScience's Innovative SNB-101 Receives FDA's Orphan Drug Designation for Gastric Cancer Treatment #South_Korea #Seongnam #SN_BioScience #Orphan_Drug #Nano_Drug

J & D Pharmaceuticals Achieves Orphan Drug Status for HCC Treatment Innovation J & D Pharmaceuticals has received Orphan Drug Designation from the FDA for its promising treatment aimed at Hepatocellular Carcinoma, a rare cancer.

J & D Pharmaceuticals Achieves Orphan Drug Status for HCC Treatment Innovation #USA #HCC #Orphan_Drug #Monmouth #J_&_D_Pharmaceuticals

Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA Kedrion's treatment for aceruloplasminemia has received Orphan Drug Designation from EMA, marking a significant advance for rare disease therapies.

Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA #Italy #Orphan_Drug #Castelvecchio_Pascoli #Kedrion #Aceruloplasminemia

Kedrion Receives Orphan Drug Designation for Rare Genetic Disorder Treatment Kedrion's innovative plasma-derived treatment for Congenital Aceruloplasminemia has received Orphan Drug Designation from EMA, highlighting a pivotal advancement for patients.

Kedrion Receives Orphan Drug Designation for Rare Genetic Disorder Treatment #Orphan_Drug #Kedrion #Aceruloplasminemia

Ribo Secures Orphan Drug Status in Europe for RBD1016 Targeting Hepatitis Delta Virus Suzhou Ribo Life Science and Ribocure Pharmaceuticals have announced that the EMA granted RBD1016 orphan drug status for HDV infections, marking a breakthrough in treatment options.

Ribo Secures Orphan Drug Status in Europe for RBD1016 Targeting Hepatitis Delta Virus #None #Orphan_Drug #Ribo #HDV_Treatment

J & D Pharmaceuticals Earns Orphan Drug Designation for ADPKD Therapy J & D Pharmaceuticals has received Orphan Drug Designation from the FDA for their investigational therapy JD-004, aimed at treating ADPKD, a rare genetic kidney disorder.

J & D Pharmaceuticals Earns Orphan Drug Designation for ADPKD Therapy #United_States #ADPKD #Orphan_Drug #JD_Pharmaceuticals #Monmouth

Amphix Bio Achieves FDA Orphan Drug Status for Revolutionary Spinal Cord Injury Treatment Amphix Bio has received FDA Orphan Drug Designation for its innovative therapeutic targeting acute spinal cord injuries, offering hope to many.

Amphix Bio Achieves FDA Orphan Drug Status for Revolutionary Spinal Cord Injury Treatment #United_States #Chicago #Orphan_Drug #Amphix_Bio #AMFX-200

IASO Bio's Equecabtagene Autoleucel Granted Orphan Drug Status by Saudi Authorities IASO Biotherapeutics' Equecabtagene Autoleucel earns Orphan Drug Designation from Saudi Food and Drug Authority to treat multiple myeloma.

IASO Bio's Equecabtagene Autoleucel Granted Orphan Drug Status by Saudi Authorities #China #Shanghai #Equecabtagene #Orphan_Drug #IASO_Biotherapeutics

Infinant Health Achieves Orphan Drug and Rare Pediatric Disease Status for NEC Treatment Infinant Health receives significant FDA designations for its drug candidate, INF108, aimed at treating necrotizing enterocolitis in premature infants, marking a pivotal step in pediatric care.

Infinant Health Achieves Orphan Drug and Rare Pediatric Disease Status for NEC Treatment #United_States #Davis #NEC #Orphan_Drug #Infinant_Health

FDA Approves Orphan Drug Status for NS-229 in Treating Rare Disease EGPA The FDA has designated NS-229 as an Orphan Drug, aimed at treating eosinophilic granulomatosis with polyangiitis (EGPA) and providing seven years of market exclusivity.

FDA Approves Orphan Drug Status for NS-229 in Treating Rare Disease EGPA #United_States #NS_Pharma #Paramus #Orphan_Drug #EGPA

GRIN Therapeutics Secures FDA Orphan Drug Status for Innovative Radiprodil Treatment GRIN Therapeutics has received Orphan Drug designation from the FDA for Radiprodil, aimed at treating GRIN-related neurodevelopmental disorders, highlighting advancements in pediatric care.

GRIN Therapeutics Secures FDA Orphan Drug Status for Innovative Radiprodil Treatment #USA #New_York #GRIN_Therapeutics #Radiprodil #Orphan_Drug